133 related articles for article (PubMed ID: 1563014)
1. Complement-dependent lysis of tumor cells by a baboon IgM antibody to a tumor-associated antigen.
Hunt KK; Shibata M; Gupta RK; Morton DL
Cancer Immunol Immunother; 1992; 34(6):377-82. PubMed ID: 1563014
[TBL] [Abstract][Full Text] [Related]
2. Cloning of a human antibody directed against human neuroblastoma cells and specific for human translation elongation factor 1alpha.
Schilbach K; Kreyenberg H; Geiselhart A; Niethammer D; Handgretinger R
Tissue Antigens; 2004 Feb; 63(2):122-31. PubMed ID: 14705983
[TBL] [Abstract][Full Text] [Related]
3. Human monoclonal antibody to tumor-associated ganglioside GD2.
Katano M; Saxton RE; Irie RF
J Clin Lab Immunol; 1984 Nov; 15(3):119-26. PubMed ID: 6099419
[TBL] [Abstract][Full Text] [Related]
4. Human monoclonal antibody to ganglioside GD2-inhibited human melanoma xenograft.
Katano M; Jien M; Irie RF
Eur J Cancer Clin Oncol; 1984 Aug; 20(8):1053-9. PubMed ID: 6540688
[TBL] [Abstract][Full Text] [Related]
5. The cytolysis of human neuroblastoma cells by a natural IgM 'antibody'-complement system in pregnancy serum.
Bolande RP; Mayer DC
Cancer Invest; 1990; 8(6):603-11. PubMed ID: 2292053
[TBL] [Abstract][Full Text] [Related]
6. Demonstration of a well-characterized tumor-associated antigen on melanoma cell surface.
Wong JH; Gupta RK; Morton DL
J Surg Oncol; 1988 Jul; 38(3):147-50. PubMed ID: 3292843
[TBL] [Abstract][Full Text] [Related]
7. Induction of antibodies to a tumor-associated antigen by immunization with a whole melanoma cell vaccine.
Euhus DM; Gupta RK; Morton DL
Cancer Immunol Immunother; 1989; 29(4):247-54. PubMed ID: 2752392
[TBL] [Abstract][Full Text] [Related]
8. Murine monoclonal IgG3 antibodies to human colorectal tumor-associated antigens: production and characterization of antibodies active in both antibody-dependent cellular cytotoxicity and complement-mediated cytolysis.
Woodhouse CS; Morgan AC
Cancer Res; 1989 May; 49(10):2766-72. PubMed ID: 2713860
[TBL] [Abstract][Full Text] [Related]
9. Antibody of patients with Guillain-Barré syndrome mediates complement-dependent cytolysis of rat Schwann cells: susceptibility to cytolysis reflects Schwann cell phenotype.
Sawant-Mane S; Estep A; Koski CL
J Neuroimmunol; 1994 Jan; 49(1-2):145-52. PubMed ID: 8294552
[TBL] [Abstract][Full Text] [Related]
10. A new recombinant single chain trispecific antibody recruits T lymphocytes to kill CEA (carcinoma embryonic antigen) positive tumor cells in vitro efficiently.
Wang XB; Zhao BF; Zhao Q; Piao JH; Liu J; Lin Q; Huang HL
J Biochem; 2004 Apr; 135(4):555-65. PubMed ID: 15115782
[TBL] [Abstract][Full Text] [Related]
11. Heparin inhibition of antibody-dependent complement-mediated lysis.
Wesolowski J; Ault K; Houghton R; Parkman R
Exp Hematol; 1984 Oct; 12(9):700-5. PubMed ID: 6237929
[TBL] [Abstract][Full Text] [Related]
12. Association between allo-immunoreactive and xeno-immunoreactive subunits of a glycoprotein tumor-associated antigen.
Euhus DM; Gupta RK; Morton DL
Cancer Immunol Immunother; 1990; 32(4):214-20. PubMed ID: 1702032
[TBL] [Abstract][Full Text] [Related]
13. Disialoganglioside GD3 on human melanoma serves as a relevant target antigen for monoclonal antibody-mediated tumor cytolysis.
Cheresh DA; Honsik CJ; Staffileno LK; Jung G; Reisfeld RA
Proc Natl Acad Sci U S A; 1985 Aug; 82(15):5155-9. PubMed ID: 3860849
[TBL] [Abstract][Full Text] [Related]
14. Humoral response of melanoma patients to two different tumor-associated antigens.
Chee DO; Gupta RK; Morton DL
J Surg Oncol; 1983 Aug; 23(4):228-35. PubMed ID: 6876798
[TBL] [Abstract][Full Text] [Related]
15. Isolation and immunochemical characterization of antibodies from the sera of cancer patients which are reactive against human melanoma cell membranes by affinity chromatography.
Gupta RK; Silver HK; Reisfeld RA; Morton DL
Cancer Res; 1979 May; 39(5):1683-95. PubMed ID: 427806
[TBL] [Abstract][Full Text] [Related]
16. Cross-reacting antigens on L5178Y cells which serve as targets for cytotoxic T-lymphocyte lysis during establishment of the tumor dormant state.
Weinhold KJ; Wheelock EF
Cancer Res; 1982 Sep; 42(9):3607-16. PubMed ID: 6179603
[TBL] [Abstract][Full Text] [Related]
17. Biological characterization of a chimeric mouse-human IgM antibody directed against the 17-1A antigen.
Fogler WE; Sun LK; Klinger MR; Ghrayeb J; Daddona PE
Cancer Immunol Immunother; 1989; 30(1):43-50. PubMed ID: 2598174
[TBL] [Abstract][Full Text] [Related]
18. IgM monoclonal antibody JD118 recognizes an inducible antigen target for human-complement-mediated cytotoxicity against neoplastic B cells.
Czuczman MS; Garin-Chesa P; Lemoli RM; Scheinberg DA
Cancer Immunol Immunother; 1993 Jun; 36(6):387-96. PubMed ID: 8500111
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of antibody-complement-mediated killing of tumor cells by hormones.
Schlager SI; Ohanian SH; Borsos T
Cancer Res; 1976 Oct; 36(10):3672-7. PubMed ID: 182362
[TBL] [Abstract][Full Text] [Related]
20. Anti-GM(2) IgM antibody-induced complement-mediated cytotoxicity in patients with dysimmune neuropathies.
Cavanna B; Jiang H; Allaria S; Carpo M; Scarlato G; Nobile-Orazio E
J Neuroimmunol; 2001 Mar; 114(1-2):226-31. PubMed ID: 11240036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
